1. Home
  2. QH vs ENSC Comparison

QH vs ENSC Comparison

Compare QH & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QH

Quhuo Limited American Depository Shares

HOLD

Current Price

$0.99

Market Cap

6.6M

ML Signal

HOLD

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$1.65

Market Cap

6.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QH
ENSC
Founded
2012
2003
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6M
6.3M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
QH
ENSC
Price
$0.99
$1.65
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.9M
82.3K
Earning Date
09-26-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.33
N/A
Revenue
$357,118,848.00
$4,487,973.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.09
N/A
Revenue Growth
N/A
1.51
52 Week Low
$0.74
$1.46
52 Week High
$169.07
$10.96

Technical Indicators

Market Signals
Indicator
QH
ENSC
Relative Strength Index (RSI) 35.81 36.37
Support Level $0.97 $1.46
Resistance Level $1.13 $1.85
Average True Range (ATR) 0.11 0.15
MACD 0.20 -0.01
Stochastic Oscillator 26.49 26.95

Price Performance

Historical Comparison
QH
ENSC

About QH Quhuo Limited American Depository Shares

Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: